Poor dental health may be linked with increased risk for diabetes, a new study suggests. The results will be presented in a poster Monday, March 19, at ENDO 2018, the 100th annual meeting of the Endocrine Society in Chicago, Ill.
Oral micronized progesterone (OMP) may diminish hot flashes and night sweats in perimenopausal women, new research from Canada reports. The results will be presented on Monday, March 19 at ENDO 2018, the 100th annual meeting of the Endocrine Society in Chicago, Ill.
Children with mild to moderate asthma do not benefit from a common practice of increasing their inhaled steroids at the first signs of an asthma exacerbation, according to clinical trial results published in The New England Journal of Medicine. Researchers found short-term increases in inhaled steroids did not prevent attacks in children aged 5 to 11, and may even slow a child’s growth.
A wearable medical patch measuring the beat-to-beat variation in heart rate is a promising device for the early detection of hypoglycemia, or low blood sugar, in type 1 diabetes, according to the researchers who tested the new monitor. Results of their preliminary study will be presented Saturday at ENDO 2018, the Endocrine Society’s 100th annual meeting in Chicago.
Scientists don’t yet grasp the intricacies of the relationship between sepsis and dementia. Candice Brown, an assistant professor in West Virginia University’s School of Medicine and Rockefeller Neuroscience Institute, is studying that relationship in order to bring about insights that help prevent or mitigate the neurological impact of sepsis.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AML
The National Institutes of Health recently awarded more than $2.4 million to a research team at the GW School of Medicine and Health Sciences, to study how cell stress in the brain could impact the risk of obesity-induced hypertension.
Two types of blood pressure medications — alpha blockers and alpha 2 agonist — show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
The study enrolled 1,754 patients in 19 countries, 51 percent of whom were male, with an average age of 70 years. After an average follow-up of 16 months, 11 percent of patients treated with dabigatran experienced a MINS-related event, compared with 15 percent of patients who received a placebo. This translates to a 28 percent reduction in risk for patients receiving dabigatran.
Using a mouse model, researchers have found mechanistic links between older stored red blood cell transfusions and subsequent bacterial pneumonia. This may reveal new approaches to improve safety of stored red blood cell transfusions. The key player is free heme, released from broken blood cells.
Researchers at Iowa State University, partnering with the LifeServe Blood Center, have used leftover blood donor cells to gain crucial insights into how natural killer cells circulating in the human body differ from those typically studied in the lab. The results of this research are published in the March 9 issue of the Journal of Biological Chemistry.
Fueled by a multimillion dollar grant from the state’s stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.
Researchers at UC Davis have shown that patients with acute myeloid leukemia (AML) who received their care at a National Cancer Institute (NCI) cancer center in California had a dramatically reduced risk of early mortality. Using data from the California Cancer Registry and the Patient Discharge Dataset, the team determined that the risk was reduced by 53 percent. These findings were reported in February in the journal Cancer.
In a clinical trial at Washington University School of Medicine, Vanderbilt University Medical Center and two medical centers in France, researchers found that a drug that revs up the immune system holds promise in treating sepsis.
Edward M. Wolin, MD, an internationally renowned authority on neuroendocrine tumors—a type of rare but increasingly frequently diagnosed cancer—has joined the Mount Sinai Health System as Director of the Center for Carcinoid and Neuroendocrine Tumors. This multidisciplinary center includes Mount Sinai specialists in gastroenterology, surgical oncology, hepatobiliary surgery, thoracic surgery, nuclear medicine, cardiology, medical oncology, radiology, pathology, endocrinology, and nutrition.
Roswell Park Comprehensive Cancer Center has been officially approved to administer an FDA-approved CAR T-cell therapy, Yescarta, to lymphoma patients.
A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning
Scientists at Washington University School of Medicine in St. Louis have used the gene-editing technology CRISPR to engineer human T cells that can attack human T cell cancers. The new approach also eliminates a dangerous side-effect called graft-versus-host disease.
Immunotherapy does not work for a majority of cancer patients. Preventing or reversing metabolic exhaustion in cancer-killing T-cells could boost its effectiveness.
Michigan State University scientists are engineering a virus-like particle, known as Qβ, that will generate anti-cancer immune responses in the body and potentially be used as a new vaccine for the treatment of cancer.
• In a group of older patients undergoing hemodialysis, cerebral blood flow declined by 10%, from before the start to the end of hemodialysis. • Cerebral blood flow declined in all brain regions that were examined, including the frontal, parietal, temporal, and occipital lobes; cerebellum; and thalamus.
Newly named unit is located within the Division of Pediatric Hematology-Oncology at Kravis Children’s Hospital at Mount Sinai
Bristol-Myers Squibb Company today announced that Yale Cancer Center has joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance translational Immuno-Oncology (I-O) science.
SBP researchers have developed the first ever high-throughput, genome-scale imaging-based approach to investigate protein stability. The method has been used to identify several previously unknown human proteins that HIV degrades to enhance its infection process.
Blood plasma samples from a mouse that received the Angptl3 CRISPR treatment (right) and a mouse that was untreated (left). The cloudiness of the sample on the left is from the high content of cholesterol and triglycerides.
Data from a new study led by University of Kentucky Markey Cancer Center researchers shows that repurposing drugs used to treat leukemia has promise for preventing melanoma metastasis.
The University of Illinois at Chicago has been awarded a $4.6 million grant from the National Heart, Lung, and Blood Institute to study the molecular neurobiology of chronic pain in patients with sickle cell disease and to develop potential new drug treatments.
Need an expert in a hurry? Need to pitch an expert in a hurry? Find experts and manage your experts in the Newswise Expert Directory. Our database of experts is growing daily. Search by institution, name, subject, keywords, and place.
Analyzing the genetics and smoking habits of more than half a million people has shed new light on the complexities of controlling blood pressure, according to a study led by researchers at Washington University School of Medicine in St. Louis.
UC Davis pathologist Hooman Rashidi is an expert in blood disorders but also a computer programmer. He has married the two disciplines and created must-have learning tools for medical students and residents. His latest is HemeQuiz1, a medical student training app.
New data from the University of Illinois at Chicago suggest that the guidelines used to evaluate an individual’s peak blood pressure response during cardiopulmonary exercise testing, which were last updated in 1996 and help doctors screen for hypertension and cardiovascular disease, may need to be revised.
Cholesterol in muscular dystrophy; synergy between alcohol and hepatitis in cholesterol levels; bacterial lipids in healthy arteries.
A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer. In a trial initiated and led by the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, tumors shrunk in 34 out of 35 patients who took the drug, and more than half of those patients saw the tumor size decrease by more than 30 percent.
One of the greatest health threats to children with sickle cell anemia is getting a dangerous bacterial infection — but most are not receiving a key medication to reduce the risk, a new study suggests.
New oncology leaders for Rutgers Cancer Institute of New Jersey at University Hospital in Newark have been named, further enhancing the facility’s expertise and ability to deliver National Cancer Institute (NCI)-designated Comprehensive Cancer Center services to the greater Essex County region.
Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer.
• In generally healthy older men, slightly lower sodium levels in the blood were related to both cognitive impairment and declines in cognitive function over time. • Additional studies are needed to determine whether correction of lower serum sodium may influence cognition in older adults.
Researchers at the University of Maryland School of Medicine have uncovered genetic mutations that may explain why people with high levels of high-density lipoprotein (HDL) cholesterol, the “good cholesterol,” have a reduced risk of coronary heart disease.
Results of a phase II study presented at the recent American Society of Hematology Annual Meeting shows the best outcomes to date for older Hodgkin lymphoma patients treated with brentuximab vedotin before and after AVD chemotherapy. A presenting author from Rutgers Cancer Institute of New Jersey shares details.
Indiana University researchers have found that certain molecules -- several of which are currently under clinical trial -- are able to "crack" the protective shell of the hepatitis B virus, suggesting it may be possible to attack the virus after its already taken hold in the body. There is currently no cure for the virus, which can cause liver failure and cancer.
Researchers have detailed, for the first time, the normal human transcriptome of the blood-nerve barrier. This barrier — a tight covering of endothelial cells — maintains the microenvironment of peripheral nerves. Knowledge of the transcriptome will aid research in peripheral nerve disease.
Moffitt Cancer Center researchers are trying to identify new drug targets to reduce the risk of GVHD. Their new study, published in the Proceedings of the National Academy of Sciences, shows a drug that targets the protein JAK2 may reduce the risk of GVHD.
UCLA researchers, in collaboration with the University of Iowa, discovered the contribution of a specific gene in the proper development of blood cells that give rise to hematopoietic stem cells. The findings identify a potential target for the development of treatments for some types of leukemia, anemia and other blood disorders.
VF Bob is a new campaign launched by the Vasculitis Foundation to honor the late Bob Sahs, one of the organization's greatest awareness advocates. The goal of the campaign is to both spread awareness about autoimmune vasculitis, and to promote the work of the Vasculitis Foundation to support patients and fund research into vasculitis.
Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia (ALL), reveal that children and young adults continued to show high rates of durable, complete remission of their disease. Most side effects were short-lived and reversible.
Results of the global, multicenter, pivotal phase 2 study that led to the first FDA approval of a gene therapy/cell therapy approach known as CAR T-cell therapy, were published today in the New England Journal of Medicine.
Researchers studied blood samples taken from patients diagnosed with sepsis and found that elevated chlorinated lipids predicted whether a patient would go on to suffer acute respiratory distress symptom (ARDS) and die within 30 days from a lung injury.
Healthy Eating Could Decrease Risk of Vertebral Fractures, Especially in Women
Castleman disease, a rare disorder of the lymph nodes and related tissues, was identified and named more than a half-century ago but, until recently, no one had written a book exclusively about it. Frits van Rhee, M.D., Ph.D., professor of medicine and director of developmental and translational medicine at the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS), has changed that.
A diet created by researchers at Rush University Medical Center may help substantially slow cognitive decline in stroke survivors, according to preliminary research presented on Jan. 25, at the American Stroke Association’s International Stroke Conference 2018 in Los Angeles. The finding are significant because stroke survivors are twice as likely to develop dementia compared to the general population.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right